BioXcel Therapeutics Inc
NASDAQ:BTAI
Cash Flow Statement
Cash Flow Statement
BioXcel Therapeutics Inc
Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||||||||||||||||||||
Net Income |
(3)
|
(2)
|
(3)
|
(5)
|
(8)
|
(11)
|
(15)
|
(19)
|
(22)
|
(28)
|
(32)
|
(33)
|
(41)
|
(54)
|
(69)
|
(82)
|
(94)
|
(100)
|
(102)
|
(107)
|
(112)
|
(122)
|
(137)
|
(166)
|
(187)
|
(203)
|
(212)
|
(179)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Stock-Based Compensation |
0
|
0
|
0
|
2
|
3
|
4
|
5
|
3
|
2
|
3
|
3
|
3
|
3
|
4
|
9
|
15
|
19
|
24
|
24
|
19
|
18
|
15
|
15
|
17
|
18
|
20
|
20
|
0
|
|
Other Non-Cash Items |
1
|
1
|
1
|
2
|
3
|
3
|
4
|
3
|
3
|
3
|
3
|
3
|
3
|
4
|
9
|
15
|
19
|
24
|
24
|
20
|
18
|
16
|
16
|
19
|
21
|
23
|
23
|
21
|
|
Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
8
|
|
Change in Working Capital |
0
|
0
|
0
|
1
|
3
|
(0)
|
0
|
3
|
1
|
6
|
5
|
3
|
4
|
7
|
7
|
1
|
0
|
(6)
|
(5)
|
5
|
(1)
|
0
|
4
|
11
|
10
|
19
|
22
|
2
|
|
Cash from Operating Activities |
(2)
N/A
|
(1)
+16%
|
(1)
+1%
|
(2)
-55%
|
(3)
-26%
|
(7)
-166%
|
(10)
-39%
|
(14)
-32%
|
(18)
-34%
|
(19)
-6%
|
(24)
-22%
|
(27)
-15%
|
(34)
-24%
|
(42)
-26%
|
(54)
-27%
|
(66)
-23%
|
(74)
-11%
|
(81)
-10%
|
(82)
-1%
|
(82)
+0%
|
(95)
-16%
|
(106)
-11%
|
(117)
-10%
|
(135)
-16%
|
(155)
-15%
|
(160)
-3%
|
(167)
-4%
|
(155)
+7%
|
|
Investing Cash Flow | |||||||||||||||||||||||||||||
Capital Expenditures |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Cash from Investing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
-50%
|
(0)
-89%
|
(1)
-176%
|
(1)
-12%
|
(1)
+2%
|
(1)
+16%
|
(0)
+67%
|
(0)
+69%
|
(0)
+44%
|
(0)
-540%
|
(1)
-94%
|
(1)
-11%
|
(1)
-1%
|
(0)
+36%
|
(0)
+44%
|
(0)
+32%
|
(0)
+6%
|
(0)
+13%
|
(0)
+86%
|
(0)
N/A
|
(0)
N/A
|
(0)
N/A
|
|
Financing Cash Flow | |||||||||||||||||||||||||||||
Net Issuance of Common Stock |
0
|
0
|
1
|
2
|
59
|
59
|
58
|
57
|
0
|
0
|
18
|
18
|
78
|
78
|
247
|
247
|
188
|
290
|
103
|
102
|
102
|
0
|
0
|
0
|
25
|
25
|
25
|
28
|
|
Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
69
|
99
|
99
|
0
|
30
|
0
|
0
|
|
Other |
2
|
1
|
1
|
1
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(3)
|
(3)
|
(1)
|
(1)
|
(1)
|
|
Cash from Financing Activities |
2
N/A
|
2
N/A
|
2
+26%
|
3
+41%
|
58
+1 791%
|
58
-1%
|
57
-1%
|
56
-2%
|
(0)
N/A
|
(0)
-83%
|
18
N/A
|
18
+1%
|
78
+336%
|
78
+0%
|
247
+217%
|
247
+0%
|
188
-24%
|
290
+54%
|
103
-65%
|
102
0%
|
102
-1%
|
66
-35%
|
96
+45%
|
96
+0%
|
120
+25%
|
55
-55%
|
24
-55%
|
27
+8%
|
|
Change in Cash | |||||||||||||||||||||||||||||
Net Change in Cash |
0
N/A
|
0
N/A
|
1
+162%
|
1
+16%
|
55
+6 203%
|
50
-10%
|
46
-7%
|
42
-10%
|
(19)
N/A
|
(20)
-6%
|
(7)
+66%
|
(10)
-48%
|
44
N/A
|
36
-19%
|
193
+444%
|
181
-6%
|
114
-37%
|
208
+82%
|
19
-91%
|
20
+2%
|
6
-68%
|
(40)
N/A
|
(21)
+48%
|
(39)
-90%
|
(35)
+11%
|
(106)
-203%
|
(142)
-34%
|
(129)
+10%
|
|
Free Cash Flow | |||||||||||||||||||||||||||||
Free Cash Flow |
(2)
N/A
|
(1)
+16%
|
(1)
+1%
|
(2)
-55%
|
(3)
-26%
|
(8)
-171%
|
(10)
-39%
|
(14)
-33%
|
(19)
-38%
|
(20)
-6%
|
(25)
-21%
|
(28)
-14%
|
(34)
-21%
|
(42)
-25%
|
(54)
-27%
|
(67)
-23%
|
(74)
-12%
|
(82)
-10%
|
(83)
-1%
|
(83)
+1%
|
(95)
-15%
|
(106)
-11%
|
(117)
-10%
|
(135)
-16%
|
(155)
-15%
|
(160)
-3%
|
(167)
-4%
|
(155)
+7%
|